CCND1 and cancer: Accordingly, it has been shown in PDAC cells and in other cancer types, that the co-inhibition of the cyclin D1 interacting kinases, CDK4/6, potentiates the global effects of KRASG12C inhibition, blocking the cell proliferation and inducing tumor regression [68,69].